ライフサイエンスコーパス: antibacterials

1 n inhibitors and prospective targets for new antibacterials.

2 em as the specific cellular target for these antibacterials.

3 is not exploited by any clinically approved antibacterials.

4 d be a target for the future design of novel antibacterials.

5 g starting point for further optimization as antibacterials.

6 gulation and potentially for intervention by antibacterials.

7 ide the bacterium is a pivotal step for most antibacterials.

8 ising the utility of the carbapenem class of antibacterials.

9 and identified from Cystobacter sp as novel antibacterials.

10 rious issues of resistance to currently used antibacterials.

11 e synergistic effects of combinations of ASL antibacterials.

12 rs such as fluoroquinolone and aminocoumarin antibacterials.

13 certain quinolones might help develop newer antibacterials.

14 esis, making LpxC a promising target for new antibacterials.

15 arget for the development of highly specific antibacterials.

16 is a suitable target for the design of novel antibacterials.

17 ns of antibacterials or ACSs with or without antibacterials.

18 alidated target for the development of novel antibacterials.

19 efore, represent potential targets for novel antibacterials.

20 cacy of available treatments and develop new antibacterials.

21 s and the target of the sulfonamide class of antibacterials.

22 excellent targets for the development of new antibacterials.

23 s sortase as a target for the development of antibacterials.

24 ng alanine racemase an attractive target for antibacterials.

25 abaceae are promising lead compounds for new antibacterials.

26 eath, making it an attractive target for new antibacterials.

27 s a renewed interest in the discovery of new antibacterials.

28 O synthase inhibitors, antitumor agents, and antibacterials.

29 nd has the potential to aid discovery of new antibacterials.

30 class of selective, nontoxic, broad-spectrum antibacterials.

31 achieve with previously reported DNA binding antibacterials.

32 uirement for a major novel scaffold class of antibacterials.

33 as lead compounds in the development of new antibacterials.

34 To address the need for new antibacterials, a number of bacterial genomes have been

35 As part of a study to optimize the quinolone antibacterials against M. tuberculosis, we have prepared

36 derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting t

37 difficulty of discovering new and effective antibacterials and the rapid development of resistance p

38 , placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days.

39 the treatment of PJI, compared with systemic antibacterials, and are not sufficient to support recomm

40 CRISPR-based antibacterials are a novel and adaptable method for buil

41 acterials or spacers with different loads of antibacterials are needed to evaluate the safety and eff

42 New antibacterials are needed to tackle antibiotic-resistant

43 cture-based strategies for developing topo2A antibacterials are suggested.

44 Novel antibacterials are urgently needed to address the growin

45 es resistance to one of the highly effective antibacterials, beta-lactams.

46 salivary flow, numerous salivary components, antibacterials (both natural and applied), fluoride from

47 is not a class effect of the fluoroquinolone antibacterials but is highly dependent upon specific sub

48 Aminoglycosides are potent antibacterials, but therapy is compromised by substantia

49 very and optimization of this novel class of antibacterials by the use of structure-guided design, mo

50 The increasing resistance to antibacterials commonly employed in the clinic and the g

51 This approach, using phages as targeted antibacterials, could extend the lifetime of our current

52 oxazolidinones are a new class of synthetic antibacterials effective against a broad range of pathog

53 We have created a class of small synthetic antibacterials, exemplified by PC190723, which inhibits

54 AU-FQ hybrids are a promising new family of antibacterials for treatment of antibiotic-resistant Gra

55 Administration of certain fluoroquinolone antibacterials has been associated with prolongation of

56 A class of antibacterials has been discovered that inhibits the gro

57 The current development of new antibacterials has lagged far behind.

58 ependent discovery of the quinolone class of antibacterials have been almost entirely overlooked by t

59 Recent studies on antibacterials have focused on the development of antimy

60 er the past forty years, efforts to discover antibacterials have yielded a wide variety of chemical s

61 difficult to imagine life without effective antibacterials; however, the inexorable rise of antibiot

62 Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA

63 Twenty publications that reported doses of antibacterials in spacers and had a follow-up of >/= 24

64 d studies evaluating the choice and doses of antibacterials in spacers.

65 shed data do not allow evaluation of whether antibacterials in temporary cement spacers provide addit

66 ing yet fascinating, and might lead to novel antibacterials in the future.

67 emphasizing the potential of nitro drugs as antibacterials in various bacterial species.

68 l IIIC and were up to 64-fold more potent as antibacterials in vitro against Gram+ bacteria.

69 Broad spectrum antibacterials, including streptomycin, rifampicin, and

70 biotics, an important new class of synthetic antibacterials, inhibit protein synthesis by interfering

71 to antibiotics and the poor pipeline of new antibacterials is creating a major health issue worldwid

72 A paucity of novel acting antibacterials is in development to treat the rising thr

73 ades, the repertoire of clinically effective antibacterials is shrinking due to the rapidly increasin

74 The mechanism of the beta-lactam antibacterials is the functionally irreversible acylatio

75 mulation affect the lethal action of diverse antibacterials, leading to the hypothesis that killing b

76 l and one of the newest clinically important antibacterials, linezolid, inhibit protein synthesis by

77 s, antiemetics, gastrointestinal stimulants, antibacterials, narcotics, antipsychotics, inotropes, di

78 n of 22 pharmacologically active substances (antibacterials, nonsteroidal antiinflammatories, antisep

79 rting point for the discovery of many of the antibacterials now in use.

80 The development of novel antibacterials, optimization of treatment approaches, im

81 either ACSs with different concentrations of antibacterials or ACSs with or without antibacterials.

82 ed trials comparing spacers with and without antibacterials or spacers with different loads of antiba

83 olidinones, totally synthetic class of novel antibacterials, possess activity against drug-resistant

84 adaptable method for building an arsenal of antibacterials potentially capable of targeting any path

85 Quinolone antibacterials represent one of medicine's most importan

86 rapped on bacterial chromosomes by quinolone antibacterials, reversible complexes form that contain D

87 presence of folate analogs (methotrexate) or antibacterials (sulfonamines) does not affect our method

88 The oxazolidinone antibacterials target the 50S subunit of prokaryotic rib

89 approach to this problem is to identify new antibacterials that act through validated drug targets s

90 al infections demands the development of new antibacterials that are not subject to existing mechanis

91 s a key step for the eventual development of antibacterials that block translocon assembly.

92 Antibacterials that disrupt cell membrane function have

93 o reversible corruption by fluoroquinolones, antibacterials that form drug-enzyme-DNA complexes in wh

94 e increases sensitivity to fluoroquinolones; antibacterials that kill cells by inhibiting topoisomera

95 Such inhibitors may represent a class of antibacterials that potentially may represent a breakthr

96 Fluoroquinolones are broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA

97 transport is vital for the discovery of new antibacterials; the finding that one amino acid change c

98 quinolones are the most commonly prescribed antibacterials, their use is threatened by an increasing

99 us success of beta-lactams as broad-spectrum antibacterials, they have never been widely used for the

100 t the threshold of regulatory innovation for antibacterials to treat drug-resistant infections, in wh

101 al information to guide selection of topical antibacterials used for empirical management of ocular i

102 The trial design, antibacterials used, and end points studied were analyze

103 acycline and ampicillin, two clinically used antibacterials, was observed.

104 Synthetic antibacterials were identified that inhibit the second e

105 The most potent antibacterials were simple hydroxybutyl and methoxybutyl

106 ide to eukaryotes is the capacity to produce antibacterials, which have evolved in prokaryotes as the

107 Fluoroquinolone antibacterials, which target DNA gyrase, are critical ag

108 e potent, broad spectrum, ribosome-targeting antibacterials whose clinical efficacy is seriously thre

109 have discovered a promising class of potent antibacterials with a previously undescribed mechanism o

110 pathway resulted in the generation of novel antibacterials with in vitro potency comparable to that

111 ompounds such as 5, 16, 19, and 21) are good antibacterials with reduced or no activity, within the d

112 ged approach investigating the metabolism of antibacterials within both the host and bacterium is out

113 chniques to study the fate of small-molecule antibacterials within the targeted organism.